PharmaSecure, a leading provider of serialization, brand protection, and patient engagement solutions, is excited to announce that it has joined the Stop TB Partnership, a group of 1300 partners around the world working to transform the fight against tuberculosis.
Participating in this partnership adds PharmaSecure’s resources to the Stop TB Partnership campaign and furthers PharmaSecure’s efforts in improving public health outcomes.
PharmaSecure’s Public Health efforts combatting Tuberculosis (TB)
Despite global progress, the Stop TB Partnership reports that there are still more than 2 billion people infected with TB in the world and 9 million new cases every year, ultimately causing 1.5 million deaths annually.
India has a high TB burden and a majority of that problem exists in the private sector. According to the World Health Organization, there were an estimated 2.1 million cases of TB in India in 2013.
PharmaSecure has been working to introduce low cost scalable solutions that help identify TB patients and then help them to complete their TB treatment as prescribed by providing adherence interventions.
PharmaSecure is currently one of the recipients of the Grand Challenges in TB Control grant from the Bill & Melinda Gates Foundation and USAID, which is designed to fund novel solutions to improve the health outcomes of patients with TB.
Through this grant program, PharmaSecure enrolled TB patients in its psConnect™ patient engagement and management platform to help them complete their treatment regimen using customized reminders and incentives. Results from the first phase of this program showed that TB patients enrolled in the program had 60% greater reported adherence to the TB regimen than non-enrolled patients.
Fighting Tuberculosis through mobile health tools
Through PharmaSecure’s psConnect™ patient engagement platform, public health professionals can understand in almost real time the adherence of TB patients to their treatment and identify obstacles to treatment completion. This gives an accurate picture of treatment results and challenges faced by patients in their course of treatment which can be used to improve public health outcomes.
PharmaSecure’s CEO, Nakul Pasricha, commented, “We are excited to be joining The Stop TB Partnership and adding our efforts to the 1300 partners working to transform the fight against TB in more than 100 countries. PharmaSecure’s public health efforts are a core part of our company and we look forward to leveraging our innovative mobile health solutions to improve public health outcomes, particularly in emerging markets at risk from TB.”
About The Stop TB Partnership:
The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership’s mission is to serve every person who is vulnerable to TB and ensure that high-quality treatment is available to all who need it.
Together our 1300 partners are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programmes, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector.
PharmaSecure was founded in the United States in 2007 with a vision to protect medicines against counterfeiting by uniquely identifying each medicine pack sold. PharmaSecure and ProductSecure mobile technology solutions protect products across industries from counterfeiting while providing intelligence on their distribution, use in emerging markets, and improving engagement with consumers of those products.
To date, PharmaSecure has protected over 2.0 billion packages for 60+ companies through serialization for brand protection, regulatory compliance, consumer and patient engagement, and market intelligence. For more information please visit www.pharmasecure.com.